Low Immunoscores CD3/CD8 and CD3/CD45RO are Associated with The Low Survival Rate of Triple Negative Breast Cancer Patients
DOI:
https://doi.org/10.24843/JBN.2025.v09.i02.p02Keywords:
CD3/CD8 immunoscore, CD3/CD45RO immunoscore, survival, triple negative breast cancerAbstract
Aim: Triple-negative breast cancer (TNBC) is associated with a highly aggressive clinical course, contributing to poorer patient outcomes and higher mortality rates. Current prognostic tools do not fully capture the complexities of the tumor immune microenvironment, particularly the role of effector lymphocytes (CD3, CD8, and CD45RO). Therefore, this study was conducted to investigate the prognostic significance of the immune markers CD3, CD8, and CD45RO within the tumor microenvironment of TNBC patients. Methods: This retrospective cohort study involved women aged >18 years old diagnosed with TNBC. Immunohistochemistry (IHC) for CD3, CD8, and CD45RO was performed using the Novolink system. Two pathologists independently assessed cell density in the tumor center (CT) and invasive margin (IM). Densities were classified as high or low using ROC curves, and the immunoscores (CD3/CD8, CD3/CD45RO) were grouped into low (I0, I1) and high (I2, I3, I4). Two-year mortality and clinical data were collected from medical records. Survival rates were analyzed using Kaplan-Meier and compared with the log-rank test. Results: The 2-year survival rate for TNBC patients was 58.3%, with a mean survival time of 18.95 months. Low CD3/CD8 was associated with significantly lower survival compared to high CD3/CD8 (42.9% vs. 73%; p=0.013), with mean survival times of 17.03 vs. 20.80 months. Similarly, low CD3/CD45RO had lower survival than high CD3/CD45RO (38.5% vs. 69.6%; p=0.01), with mean survival times of 16.37 vs. 20.43 months. Conclusion: Low CD3/CD8 and CD3/CD45RO immunoscores are associated with low survival in TNBC patients.
References
1. The Clobal Cancer Observatory. Breast Cancer Factsheets based on Globocan 2020 - International Agency for Reaserch on Cancer (WHO). 2020
2. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and Mortality of Female Breast Cancer in The Asia-Pacific Region. Cancer Biol Med. 2014;11:101-15
3. Foulkes WD. Triple-Negative Breast Cancer. N Engl J Med. 2010;363(20): 1938–48
4. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–102
5. Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol. 2010;22:215-22
6. Kwak Y, Koh J, Kim D, Kang S, Kim W, Lee H. Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. Oncotarget. 2016;7:81778-90
7. Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128-39
8. Angell H, Galon J. From the immune contexture to the immunoscore: The role of prognostic and predictive immune markers in cancer. Current Opinion in Immunology. 2013;25(2):261–7
9. Anitei M-G, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi A-M, et al. Prognostic and predictive values of the Imunoskor in patients with rectal cancer. Clin Cancer Res. 2014;20:1891–9
10. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005;47(4):458–72.
11. Widodo I, Dwianingsih EK, Aryandono T, Soeripto S. Clinicopathological Characteristic and Prognostic Significance of Indonesian Triple Negative Breast Cancer. Indones Biomed J. 2019;11(3):286–92.
12. Tsiatas M, Kalogeras KT, Manousou K, Wirtz RM, Gogas H, Veltrup E, et al. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Cancer Medicine. 2018;7:5066-82
13. Vuger AT, Separovic R, Vazdar L, Pavloic M, Lepetic P, Sitic S, et al. Characteristics and prognosis of triple-negative breast cancer patients: a croatian single institution retrospective cohort study. Acta Clin Croat. 2020;59(1):97-108
14. Da Costa REAR, de Oliveira FTR, Araujo ALN, Vieira SC. Prognostic factors in triple- negative breast cancer: a retrospective cohort. Rev Assoc Med Bras. 2021;67(7):950- 957
15. Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, et al. CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci. 2020;21(18): 6968
16. Raskov H, Orhan A, Christensen JP, Gogenur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Brithis Journal of Cancer. 2021;124:359-367
17. Philip M, Schietinger A. CD8+T cell differentiation and dysfunction in cancer. Nat Rev Imm. 2022;22:209-223
18. Singh A, Dees S, Grewal IS. Overcoming the challenges associated with CD3+ T-cell redirection in cancer. British Journal of Cancer. 2021; 124-1037-48
19. Ren X, Song Y, Pang J, Chen L, Zhou L, Liang Z, et al. Prognostic value of various immune cells and immunoscore in triple-negative breast cancer. Front Immunol. 2023;14:1137561
20. Rapoport BL, Nayler S, Mlcnik B, Mlecnik B, Smit T, Heyman L, et al. Tumor- infiltrating lymphocytes (TIL) in early breast cancer patients: high CD3+, CD8+, and immunoscore are associated with a pathological complete response. Cancers (Basel). 2022;14(10):2525
21. Hu G, Wang S. Tumor-infiltrating CD45RO+ memory T Lumphocytes predict favorable clinical outcome in solid tumors. Sci Rep. 2017;7(1): 10376
22. Wu K, Zheng X, Yao Z, Zheng Z, Huang W, Mu X, et al. Accumulation of CD45RO+CD8+ T cells is a diagnostic and prognostic biomarker for clear cell renal cell carcinoma. Aging (Albany NY). 2021;13(10):14304 – 14321
23. Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. British Journal of Cancer. 2011;105:1191-6
24. Wang M. Imunoskor predicts gastric cancer postsurgical outcome. Lancet Oncol. 2017;18(2): e68.
25. Woodland DL, Kohlmeier JE. Migration, maintenance, and recall of memory T cells in peripheral tissues. Nature Reviews Immunology. 2009;9:153-61
26. Sun H, Zou J, Chen L, Zu X, Wen G, Zhong J. Triple‑negative breast cancer and its? association with obesity (Review). Mol Clin Oncol. 2017;935–42
27. Ahmadvand S, Faghih Z, Montazer M, Safaei A, Mokhtari M, Jafari P, et al. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients. Cellular Oncology. 2019;42(3s): 343-56
28. Panigoro SS, Maulanisa SC, Kurnia A, Purwanto DJ, Rustamadji P, Herqutanto H, et al. Total and Intratumoral CD8+ T Cell Expressions are Correlated with Miller Payne Grading and WHO Clinical Response of Neoadjuvant Chemotherapy. Indones Biomed J. 2023;15(2):171–8.
29. Yajima R, Yajima T, Fuji T, Fujii T, Yanagita Y, Fujisawa T, et al. Tumor- infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer. Breast Cancer. 2015:1-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 JBN (Jurnal Bedah Nasional)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
